Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A study in adult patients with Cardiovascular disease or at elevated risk of having Cardiovascular disease to evaluate whether the study drug (Dalcetrapib) is able to reduce the risk of experiencing a cardiovascular event in the future such as a heart attack or a stroke by raising HDL cholesterol (also called “good”cholesterol)
To evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in adult patients with stable coronary heart disease (CHD), CHD risk equivalents or at elevated risk for cardi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
APHINITY : Essai de phase 3, randomisée, en double aveugle, évaluant l’efficacité et la tolérance de l’ajout du pertuzumab à une chimiothérapie associée à du trastuzumab, chez des patientes ayant un cancer du sein primitif HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai suspendu] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un traitement associant du pertuzumab à une chimiothérapie standard et à du trastuzumab, comme traitement adjuvant, chez des patien...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Limited
Update Il y a 4 ans
A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis (RA)
To investigate the effect of TCZ on markers of atherogenic risk in patients with RA. Primary objectives: • To investigate the effect of 12 weeks of treatment with TCZ on small LDL-L1 particle number •...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienced patients
• To evaluate the induction strategy of HAART alone (I1) compared to enfuvirtide (90 mg s.c.BID) in combination with HAART (ENF+HAART, I2) • To determine the overall induction/maintenance treatment s...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
Étude MO25757 : étude de phase 4, évaluant l’efficacité et la tolérance d’un traitement par bevacizumab en monothérapie ou en association avec un autre traitement anticancéreux, chez des patients ayant reçu du bevacizumab pour une tumeur solide dans le cadre d’une étude clinique promue par Hoffmann-La Roche et/ou Genentech. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cette étude est d’évaluer l’efficacité et la tolérance d’un traitement par du bevacizumab seul ou en association avec un autre traitement anticancéreux, chez des patients ayant déjà reçu...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)
• To demonstrate superior clinical efficacy as measured by progression free survival (PFS) of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus R-CHOP alone for the treatment of pre...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
To determine the effect of RO0506997 on MS by assessing the number of new gadolinium-enhancing lesions developing while on treatment (specifically the sum of new lesions seen on the weeks 4, 8 and 12 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with advanced gastric cancer
To compare the overall survival (OS) for patients treated with capecitabine and cisplatin combined with bevacizumab, versus capecitabine and cisplatin plus placebo (for bevacizumab).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease
The primary objective is to determine the effect of taspoglutide in addition to standard of care on cardiovascular outcomes in type 2 diabetic subjects with established cardiovascular disease in order...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris ESTUDIO RANDOMIZADO, DOBLE CIEGO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE RITUXIMAB EN COMPARACION CON MMF EN PACIENTES CON PÉNFIGO VULGAR
To evaluate the efficacy of rituximab compared with MMF in achieving sustained complete remission, evaluated by the Pemphigus Disease Area Index (PDAI; see Section 3.4.1.1), and assessed at Week 52 in...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next